WA
PVLA

WPG Advisers’s Palvella Therapeutics PVLA Stock Holding History

WPG Advisers’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$997 Buy
8
+1
+14% +$104 ﹤0.01% 1257
2025
Q4 		$733 Buy
+7
New +$597 ﹤0.01% 1338

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WPG Advisers's PVLA Position: Q1 2026 in Review

WPG Advisers increased its Palvella Therapeutics (PVLA) stake by 14% in Q1 2026, buying an estimated $104 and bringing the position to 8 shares worth $997. The position accounts for ﹤0.01% of the portfolio, ranked #1257.

WPG Advisers first reported a position in PVLA in Q4 2025 and has held it in 2 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • WPG Advisers held 8 shares of Palvella Therapeutics worth $997 as of Q1 2026.
  • WPG Advisers bought 1 Palvella Therapeutics share in Q1 2026, an estimated $104.
  • Palvella Therapeutics made up ﹤0.01% of WPG Advisers's portfolio in Q1 2026, its #1257 holding.
  • WPG Advisers first reported a position in Palvella Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on WPG Advisers's 13F filing for Q1 2026, filed 30 Apr 2026.